冷极射频序贯索拉非尼与索拉非尼单药治疗进展期肝细胞癌的对比研究

Comparative Study of Radiofrequency Ablation plus Sorafenib Treatment and Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma

目的比较冷极射频序贯索拉非尼与索拉非尼单药治疗进展期肝细胞癌的疗效和不良反应。方法将22例晚期肝细胞癌患者随机分为观察组(10例,冷极射频序贯索拉非尼治疗)和对照组(12例,索拉非尼单药治疗),治疗3个月后比较两组患者的治疗有效率、临床获益率及生存期;同时观察比较两组患者的不良反应。结果治疗后观察组的治疗有效率为60.0%,临床获益率为80.0%;对照组的治疗有效率为8.3%,临床获益率为66.7%,观察组的有效率及临床获益率较高(P<0.05);且观察组的6、12个月生存率及中位无进展生存时间均优于于对照组(P<0.05);两组患者的不良反应发生率差别无统计学意义(P>0.05)。结论与索拉非尼单药治疗相比较,冷极射频序贯索拉非尼治疗进展期肝细胞癌疗效更好,安全性相似,值得临床推广应用。

Objective To compare the clinical effect and adverse effects between Radiofrequency ablation plus Sorafenib treatment and Sorafenib monotherapy for advanced hepatocellular carcinoma. Methods 22 patients with advanced liver cancer were randomly divided into two groups, one is observation group, with 10 cases, given Radiofrequency ablation plus Sorafenib treatment, and one is control group, with 12 cases, given Sorafenib monotherapy. After three months treatment, the treatment effciency, clinical benefit rate and survival rate of the two groups were compared. Results The treatment effciency was 60.0% in observation group, but 8.3% in control group （P〈0.05）. The clinical benefit rate was 80.0% in observation group, but 66.7% in control group （P〈0.05）. The 6 and 12-month survival rate was higher and median progression-free survival time was longer in observation group than in control group （P〈0.05）. And there was no significant difference between the incidences of adverse reactions of the two groups （P〉 0.05）. Conclusion Compared with Sorafenib used alone, radiofrequency ablation in combination with Sorafenib has better efficacy and similar safety in advanced hepatocellular carcinoma treatment. It deserves clinical application.